Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
miR-129-5p mimic
- Development stage
- Preclinical
- Modality
- MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intratumoral, Intravenous
01
Overview
miR-129-5p mimic is a research-grade synthetic double-stranded RNA molecule designed to replicate the biological activity of the endogenous mature microRNA miR-129-5p. As a microRNA replacement therapy, it functions by binding to the 3' untranslated regions (UTRs) of specific target mRNAs, leading to translational inhibition or mRNA degradation. Key targets include the anti-apoptotic protein BCL2 and the pro-inflammatory mediator HMGB1. In preclinical oncology research, miR-129-5p mimic has demonstrated the ability to inhibit cell proliferation, induce apoptosis, and sensitize cells to chemotherapy in various malignancies, including non-small cell lung cancer (NSCLC), glioblastoma, and colorectal cancer. While widely used as a laboratory research tool from suppliers like Sigma-Aldrich and Thermo Fisher, it is not currently a branded pharmaceutical product in clinical development.
- Other names
- microRNA-129-5p mimicmicroRNA129-5p mimicmicroRNA 129-5p mimichsa-miR-129-5p mimichsa-miR129-5p mimichsa-miR 129-5p mimicmiR-129 mimicmiR129 mimicmiR 129 mimic
02
Targets
BCL-2 (BCL-2 family)
Beyond the preview
Go deeper on miR-129-5p mimic.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on miR-129-5p mimic.